Old drugs to stop breast cancer metastasis
El Mundo newspaper has published an article on a study by the University of Basel (Switzerland) that has found a way to separate the tumour cells that circulate in blood in groups and to prevent them from forming metastases. In this regard, they include the opinion of Roger Gomis, ICREA researcher at IRB Barcelona: "(This study) allows us to understand how to handle the aggregated cells that initiate the tumour, but now we need more effective and clinically optimal compounds. It is another step in a very fertile field such as the cells in circulation, but we must be realistic in terms of expectations. There is a gulf between what we see in the laboratory and what can be done with patients later on. "
Related content
News
The mechanism unveiled triggers a mutation fog, causing hundreds of mutations in each tumor, which spread through the genome of lung, head-and-neck and breast cancers.
Researchers from the Genome Data Science Lab have identified the antiviral APOBEC3A enzyme as the major cause of this new type of hypermutation.
Published in Nature Genetics, the study shows how the mutation fog process generates many oncogenic “cancer driver” mutations, thus accelerating tumour development.
Researchers at IRB Barcelona discover a new mechanism in estrogen receptor-positive breast cancer cells.
The inhibition of CPEB2, a key factor in the estrogen signalling pathway, causes cancer cells to proliferate less and protects mice against luminal breast cancer.
To mark World Cancer Day, the programme El Matí de Barcelona Betevé broadcasted by Radio Barcelona has interviewed Roger Gomis, ICREA Researcher and head of the Growth Control and Metastasis Lab at IRB Barcelona. During the interview, he talked about metastasis, the process by which a tumour spreads to the rest of the body, allowing cancer cells to adapt to new environments “What we are focusing on in our lab is precisely how this cell adaptation and plasticity comes about,” says Gomis.
